Clinical Trials for Aragon Pharmaceuticals

Explore 5 clinical trials worldwide

Showing 1-5 of 5 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Aragon Pharmaceuticals

Clinical Trials (5)

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

PHASE3Active, not recruiting

1,052 participants

Started: Nov 27, 2015 · Completed: Dec 31, 2027

1 condition1 sponsor222 locations

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

PHASE3Active, not recruiting

1,503 participants

Started: Nov 19, 2015 · Completed: Dec 29, 2028

1 condition1 sponsor262 locations

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

PHASE3Active, not recruiting

982 participants

Started: Nov 26, 2014 · Completed: Dec 31, 2027

1 condition1 sponsor173 locations

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

PHASE1Active, not recruiting

57 participants

Started: Jul 9, 2014 · Completed: Dec 31, 2027

2 conditions1 sponsor7 locations

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

PHASE3Active, not recruiting

1,207 participants

Started: Oct 14, 2013 · Completed: Dec 31, 2027

1 condition1 sponsor379 locations